Differences in the Circulating Proteome in Individuals with versus without Sickle Cell Trait.


Journal

Clinical journal of the American Society of Nephrology : CJASN
ISSN: 1555-905X
Titre abrégé: Clin J Am Soc Nephrol
Pays: United States
ID NLM: 101271570

Informations de publication

Date de publication:
01 Nov 2023
Historique:
received: 25 03 2023
accepted: 26 07 2023
pmc-release: 01 11 2024
medline: 9 11 2023
pubmed: 3 8 2023
entrez: 3 8 2023
Statut: ppublish

Résumé

Sickle cell trait affects approximately 8% of Black individuals in the United States, along with many other individuals with ancestry from malaria-endemic regions worldwide. While traditionally considered a benign condition, recent evidence suggests that sickle cell trait is associated with lower eGFR and higher risk of kidney diseases, including kidney failure. The mechanisms underlying these associations remain poorly understood. We used proteomic profiling to gain insight into the pathobiology of sickle cell trait. We measured proteomics ( N =1285 proteins assayed by Olink Explore) using baseline plasma samples from 592 Black participants with sickle cell trait and 1:1 age-matched Black participants without sickle cell trait from the prospective Women's Health Initiative cohort. Age-adjusted linear regression was used to assess the association between protein levels and sickle cell trait. In age-adjusted models, 35 proteins were significantly associated with sickle cell trait after correction for multiple testing. Several of the sickle cell trait-protein associations were replicated in Black participants from two independent cohorts (Atherosclerosis Risk in Communities study and Jackson Heart Study) assayed using an orthogonal aptamer-based proteomic platform (SomaScan). Many of the validated sickle cell trait-associated proteins are known biomarkers of kidney function or injury ( e.g. , hepatitis A virus cellular receptor 1 [HAVCR1]/kidney injury molecule-1 [KIM-1], uromodulin [UMOD], ephrins), related to red cell physiology or hemolysis (erythropoietin [EPO], heme oxygenase 1 [HMOX1], and α -hemoglobin stabilizing protein) and/or inflammation (fractalkine, C-C motif chemokine ligand 2/monocyte chemoattractant protein-1 [MCP-1], and urokinase plasminogen activator surface receptor [PLAUR]). A protein risk score constructed from the top sickle cell trait-associated biomarkers was associated with incident kidney failure among those with sickle cell trait during Women's Health Initiative follow-up (odds ratio, 1.32; 95% confidence interval, 1.10 to 1.58). We identified and replicated the association of sickle cell trait with a number of plasma proteins related to hemolysis, kidney injury, and inflammation.

Sections du résumé

BACKGROUND BACKGROUND
Sickle cell trait affects approximately 8% of Black individuals in the United States, along with many other individuals with ancestry from malaria-endemic regions worldwide. While traditionally considered a benign condition, recent evidence suggests that sickle cell trait is associated with lower eGFR and higher risk of kidney diseases, including kidney failure. The mechanisms underlying these associations remain poorly understood. We used proteomic profiling to gain insight into the pathobiology of sickle cell trait.
METHODS METHODS
We measured proteomics ( N =1285 proteins assayed by Olink Explore) using baseline plasma samples from 592 Black participants with sickle cell trait and 1:1 age-matched Black participants without sickle cell trait from the prospective Women's Health Initiative cohort. Age-adjusted linear regression was used to assess the association between protein levels and sickle cell trait.
RESULTS RESULTS
In age-adjusted models, 35 proteins were significantly associated with sickle cell trait after correction for multiple testing. Several of the sickle cell trait-protein associations were replicated in Black participants from two independent cohorts (Atherosclerosis Risk in Communities study and Jackson Heart Study) assayed using an orthogonal aptamer-based proteomic platform (SomaScan). Many of the validated sickle cell trait-associated proteins are known biomarkers of kidney function or injury ( e.g. , hepatitis A virus cellular receptor 1 [HAVCR1]/kidney injury molecule-1 [KIM-1], uromodulin [UMOD], ephrins), related to red cell physiology or hemolysis (erythropoietin [EPO], heme oxygenase 1 [HMOX1], and α -hemoglobin stabilizing protein) and/or inflammation (fractalkine, C-C motif chemokine ligand 2/monocyte chemoattractant protein-1 [MCP-1], and urokinase plasminogen activator surface receptor [PLAUR]). A protein risk score constructed from the top sickle cell trait-associated biomarkers was associated with incident kidney failure among those with sickle cell trait during Women's Health Initiative follow-up (odds ratio, 1.32; 95% confidence interval, 1.10 to 1.58).
CONCLUSIONS CONCLUSIONS
We identified and replicated the association of sickle cell trait with a number of plasma proteins related to hemolysis, kidney injury, and inflammation.

Identifiants

pubmed: 37533140
doi: 10.2215/CJN.0000000000000257
pii: 01277230-202311000-00008
pmc: PMC10637465
doi:

Substances chimiques

Proteome 0
Biomarkers 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1416-1425

Subventions

Organisme : NHLBI NIH HHS
ID : HHSN268201100037C
Pays : United States
Organisme : NHLBI NIH HHS
ID : 75N92021D00002
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL120393
Pays : United States
Organisme : WHI NIH HHS
ID : 75N92021D00005
Pays : United States
Organisme : NHLBI NIH HHS
ID : HHSN268201800014I
Pays : United States
Organisme : NHGRI NIH HHS
ID : U01-HG011720
Pays : United States
Organisme : NHLBI NIH HHS
ID : HHSN268201800014C
Pays : United States
Organisme : NHLBI NIH HHS
ID : 75N92021D00001
Pays : United States
Organisme : WHI NIH HHS
ID : 75N92021D00003
Pays : United States
Organisme : NIMHD NIH HHS
ID : R01-MD012765
Pays : United States
Organisme : NHLBI NIH HHS
ID : HHSN268201800015I
Pays : United States
Organisme : NIMHD NIH HHS
ID : R01 MD012765
Pays : United States
Organisme : NHLBI NIH HHS
ID : HHSN268201800010I
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL117626
Pays : United States
Organisme : NHLBI NIH HHS
ID : HHSN268201800011I
Pays : United States
Organisme : WHI NIH HHS
ID : 75N92021D00004
Pays : United States
Organisme : NHLBI NIH HHS
ID : HHSN268201800012I
Pays : United States
Organisme : NHLBI NIH HHS
ID : HHSN268201800012C
Pays : United States
Organisme : NHLBI NIH HHS
ID : U01 HL120393
Pays : United States
Organisme : NIDDK NIH HHS
ID : R01 DK117445
Pays : United States
Organisme : NHLBI NIH HHS
ID : HHSN268201800001C
Pays : United States
Organisme : NHGRI NIH HHS
ID : U01 HG011720
Pays : United States
Organisme : NIMHD NIH HHS
ID : HHSN268201800013I
Pays : United States
Organisme : NIDDK NIH HHS
ID : R01-DK117445
Pays : United States
Organisme : NHLBI NIH HHS
ID : HHSN268201800011C
Pays : United States

Commentaires et corrections

Type : CommentIn

Informations de copyright

Copyright © 2023 by the American Society of Nephrology.

Références

Immunol Lett. 2020 Aug;224:1-11
pubmed: 32437728
Blood. 1986 Nov;68(5):985-90
pubmed: 3533181
Blood. 2018 Oct 11;132(15):1621-1625
pubmed: 30139825
J Am Soc Nephrol. 2017 Jul;28(7):2180-2187
pubmed: 28280138
Front Physiol. 2021 Mar 03;12:645650
pubmed: 33746781
Nat Med. 2019 May;25(5):805-813
pubmed: 31011203
Curr Opin Nephrol Hypertens. 2021 Nov 1;30(6):531-537
pubmed: 34475336
Circulation. 2022 Feb;145(5):357-370
pubmed: 34814699
Am J Kidney Dis. 2003 Dec;42(6 Suppl 5):A5-7, S1-230
pubmed: 14655179
Sovrem Tekhnologii Med. 2021;13(3):64-78
pubmed: 34603757
PLoS Genet. 2018 Mar 28;14(3):e1007293
pubmed: 29590102
PLoS One. 2014 Apr 22;9(4):e95192
pubmed: 24755770
Clin Sci (Lond). 2021 Sep 17;135(17):2127-2142
pubmed: 34462781
Innovation (Camb). 2021 Jul 01;2(3):100141
pubmed: 34557778
Arterioscler Thromb Vasc Biol. 2017 Nov;37(11):2220-2227
pubmed: 28912365
J Thromb Haemost. 2015 Jan;13(1):2-9
pubmed: 25393788
Nat Commun. 2021 Nov 24;12(1):6822
pubmed: 34819519
JAMA. 2014 Nov 26;312(20):2115-25
pubmed: 25393378
Nat Rev Nephrol. 2016 Jun;12(6):325-38
pubmed: 27108839
Nat Genet. 2020 Oct;52(10):1122-1131
pubmed: 32895551
Control Clin Trials. 1998 Feb;19(1):61-109
pubmed: 9492970
Trends Mol Med. 2016 Mar;22(3):200-213
pubmed: 26875449
Clin J Am Soc Nephrol. 2022 May;17(5):684-692
pubmed: 35474272
Free Radic Biol Med. 2004 Oct 15;37(8):1097-104
pubmed: 15451051
Am J Hum Genet. 2021 Oct 7;108(10):1836-1851
pubmed: 34582791
Blood Cells Mol Dis. 2015 Mar;54(3):297-301
pubmed: 25500149
Expert Rev Hematol. 2017 Dec;10(12):1087-1094
pubmed: 29048948
Pflugers Arch. 2022 Aug;474(8):771-781
pubmed: 35881244
Am J Kidney Dis. 2010 Apr;55(4):622-7
pubmed: 20338463
Am J Med. 2022 Aug;135(8):e279-e287
pubmed: 35461807
Kidney Dis (Basel). 2022 Jun 8;8(4):265-274
pubmed: 35949208
Front Immunol. 2021 Jun 07;12:664202
pubmed: 34163473
Int J Hematol. 2015 Feb;101(2):114-8
pubmed: 25480631
N Engl J Med. 2016 Aug 4;375(5):435-42
pubmed: 27518662
Front Genet. 2021 Nov 08;12:682929
pubmed: 34819944
Nat Rev Nephrol. 2022 Jun;18(6):361-377
pubmed: 35190716
J Am Soc Nephrol. 2023 Jan 1;34(1):122-131
pubmed: 36288905
Am J Med. 2009 Jun;122(6):507-12
pubmed: 19393983
Sci Adv. 2022 Aug 19;8(33):eabm5164
pubmed: 35984888
Kidney Int. 2022 Aug;102(2):370-381
pubmed: 35618095
Am J Kidney Dis. 2021 Jul;78(1):75-84.e1
pubmed: 33388403
J Am Soc Nephrol. 2021 Sep;32(9):2291-2302
pubmed: 34465608
Oxid Med Cell Longev. 2022 Oct 12;2022:7686956
pubmed: 36275899
J Clin Invest. 2017 Mar 1;127(3):750-760
pubmed: 28248201
Blood. 2021 Sep 30;138(13):1162-1171
pubmed: 34166491
Int J Mol Sci. 2021 Feb 18;22(4):
pubmed: 33670516

Auteurs

Yanwei Cai (Y)

Division of Public Health Sciences, Fred Hutchinson Cancer Center, Seattle, Washington.

Nora Franceschini (N)

Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina, Chapel Hill, North Carolina.

Aditya Surapaneni (A)

Department of Epidemiology and Welch Center for Prevention, Epidemiology, & Clinical Research, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland.
Welch Center for Prevention, Epidemiology, & Clinical Research, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland.

Melanie E Garrett (ME)

Duke Molecular Physiology Institute, Duke University Medical Center, Durham, North Carolina.

Usman A Tahir (UA)

Division of Cardiovascular Medicine, Beth Israel Deaconess Medical Center, Boston, Massachusetts.
Broad Institute of Harvard University and Massachusetts Institute of Technology, Cambridge, Massachusetts.

Li Hsu (L)

Division of Public Health Sciences, Fred Hutchinson Cancer Center, Seattle, Washington.

Marilyn J Telen (MJ)

Duke Molecular Physiology Institute, Duke University Medical Center, Durham, North Carolina.
Division of Hematology, Department of Medicine, Duke University Medical Center, Durham, North Carolina.

Bing Yu (B)

School of Public Health, The University of Texas Health Science Center at Houston, Houston, Texas.

Hua Tang (H)

Department of Genetics, Stanford University School of Medicine, Stanford, California.

Yun Li (Y)

Department of Genetics, University of North Carolina, Chapel Hill, North Carolina.

Simin Liu (S)

Center for Global Cardiometabolic Health, Departments of Epidemiology, Medicine, and Surgery, Brown University, Providence, Rhode Island.

Robert E Gerszten (RE)

Division of Cardiovascular Medicine, Beth Israel Deaconess Medical Center, Boston, Massachusetts.
Broad Institute of Harvard University and Massachusetts Institute of Technology, Cambridge, Massachusetts.

Josef Coresh (J)

Department of Epidemiology and Welch Center for Prevention, Epidemiology, & Clinical Research, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland.
Welch Center for Prevention, Epidemiology, & Clinical Research, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland.

JoAnn E Manson (JE)

Brigham and Women's Hospital, Harvard Medical School, Harvard T.H. Chan School of Public Health, Boston, Massachusetts.

Genevieve L Wojcik (GL)

Department of Epidemiology and Welch Center for Prevention, Epidemiology, & Clinical Research, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland.

Charles Kooperberg (C)

Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina, Chapel Hill, North Carolina.

Paul L Auer (PL)

Division of Biostatistics, Institute for Health and Equity, and Cancer Center, Medical College of Wisconsin, Milwaukee, Wisconsin.

Matthew W Foster (MW)

Division of Pulmonary, Allergy and Critical Care, Department of Medicine, Duke University Medical Center, Durham, North Carolina.

Morgan E Grams (ME)

Division of Precision Medicine, New York University Grossman School of Medicine, New York, New York.

Allison E Ashley-Koch (AE)

Duke Molecular Physiology Institute, Duke University Medical Center, Durham, North Carolina.

Laura M Raffield (LM)

Department of Genetics, University of North Carolina, Chapel Hill, North Carolina.

Alex P Reiner (AP)

Division of Public Health Sciences, Fred Hutchinson Cancer Center, Seattle, Washington.
Department of Epidemiology, University of Washington, Seattle, Washington.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH